Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 111.11% year-on-year.
Undervalued
The company’s latest PE is -9.73, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 103.26M shares, increasing 16.93% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 194.83K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.46.